# US 2025/0367232 A1 · Halogen treatment of heart attack and ischemic injury

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367232 A1
- Document ID: US20250367232A1
- Status: Published application
- Kind: A1
- Application number: 19/008,094
- Filed: 2025-01-02
- Published: 2025-12-04
- Earliest claimed: 2014-02-10
- Assignees: Fred Hutchinson Cancer Research Center
- Applicants: Fred Hutchinson Cancer Research Center
- Inventors: Mark B. ROTH; Michael L. MORRISON; Akiko IWATA
- Web page: https://patentgrep.com/patent/US20250367232A1

## CPC

- A61K 33/18: Iodine; Compounds thereof
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 33/04: Sulfur, selenium or tellurium; Compounds thereof
- A61K 33/16: Fluorine compounds
- A61K 38/063: {Glutathione}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/06: Antiarrhythmics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 27/12: for cataracts
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to the use of halogen compounds, including iodide, and chalcogenide compounds, including iodide, sulfide and selenide, to treat and prevent diseases and injuries. The present invention further relates to compositions comprising a halogen compound and/or a chalcogenide compound, including pharmaceutical compositions, as well as methods of manufacturing such compounds and administering such compositions to subjects in need thereof.

## Claims

### Claim 1

A method for treating or preventing an injury or disease in a subject, comprising providing to said subject a composition comprising a halogen compound and a pharmaceutically acceptable carrier, diluent, or excipient, wherein the halogen compound is an iodide.

### Claim at position 2

-5. (canceled)

### Claim 6 (depends on 1)

The method of claim 1, wherein said iodide is sodium iodide, potassium iodide, hydrogen iodide, calcium iodide, or silver iodide.

### Claim at position 4

-13. (canceled)

### Claim 14 (depends on 1)

The method of claim 1, wherein said composition is formulated for intravenous administration, administration by infusion, or oral administration and wherein the composition comprises a stable reduced form of the halogen compound.

### Claim 15 (depends on 1)

The method of claim 1, wherein said composition is provided to the subject in an amount sufficient to increase the blood concentration of the halogen at least 100%, at least 200%, at least 300%, at least 400%, or at least 500% for at least some time.

### Claim 16 (depends on 1)

The method of claim 1, wherein said disease or injury is selected from any of the following, or is caused by or results from any of the following: ablation therapy, adrenalectomy, aortic aneurysm, aortic root surgery, aortic stenosis, aortic valve disease, arrhythmia, atherosclerosis, atrial flutter, atrial fibrillation, atrial septal defect, arteriovenous malformation, awake brain surgery, bariatric surgery, bone marrow transplant, brachial plexus injuries, bradycardia, brain aneuryism, breast augmentation surgery, breast reduction surgery, burn injury, coronary bypass surgery, cataract, coronary artery disease, cardiac ablation, cardiac catheterization, cardiac resynchronization therapy, cardiac surgery, cardiomyopathy, cardiac surgery, cardiovascular diseases, carotid angioplasty and stenting, coarctation of the aorta, congenital heart disease, coronary bypass surgery, coronary artery disease, critical care medicine, chronic obstructive pulmonary disease, Ebola virus, elbow replacement surgery, emergency medicine, epilepsy, general internal medicine, general surgery, gastrointestinal bleeding, graft versus host disease, Hanta pulmonary virus (HPV), heart attack, heart transplant, heart valve surgery, hip replacement surgery, hypertrophic cardiomyopathy, hypoxia ischemia encephalopathy, hysterectomy, ileoanal anastomosis (j pouch) surgery, ileus, post-operative ileus, inflammatory bowel disease, ischemic heart disease, ischemia reperfusion injury, irritable bowel syndrome, jaw surgery, kidney transplant, laryngotracheal reconstruction surgery, liver transplant, lung volume reduction surgery, lung transplant, minimally invasive heart surgery, noise-induced hearing loss, neurosurgery, oral and maxillofacial surgery, orthopedic surgery, pancreas transplant, pancreatitis, partial nephrectomy, pediatric cervical spine surgery, pediatric surgery, pelvic organ prolapse, peripheral vascular disease, plastic and reconstructive surgery, pulmonary and critical care medicine, pulmonary atresia, pulmonary vein isolation, radiation-inducd lung injury, rectal prolapse, restrictive cardiomyopathy, retinal detachment, retinopathy of prematurity, robotic surgery, Salmonella infection, surgical adhesion, sickle cell anemia, sickle cell crisis, ST segment elevation myocardial infarction (STEMI), stem cell engraftment, spinal cord injury, spontaneous coronary artery dissection, spontaneous occlusion of the circle of willis, stroke, stroke telemedicine (telestroke), sudden cardiac arrest, stereotactic radiosurgery, surgery, chronic heart failure, systolic heart failure, tachycardia, teare's disease, thoracic aortic aneurysm, thoracic surgery, total elbow arthroplasty, tricuspid valve disease, ulcerative colitis, valve-preserving aortic root repair, vascular and endovascular surgery, vascular medicine, ventilator-induced lung injury, or ventricular tachycardia.

### Claim 17 (depends on 1)

The method of claim 1, wherein said injury or disease is selected from, results from or is caused by inflammation, immune response, heart attack, coronary bypass surgery, ischemia, gut ischemia, liver ischemia, kidney ischemia, hypoxic-ischemic encephalopathy, stroke, traumatic brain injury, limb ischemia, eye ischemia, sepsis, smoke, burn, reperfusion, or acute lung injury.

### Claim 18 (depends on 17)

The method of claim 17, wherein said injury is an infarct caused by a heart attack or a stroke.

### Claim 19 (depends on 16)

The method of claim 16, wherein said injury is caused by coronary bypass surgery, optionally a coronary artery bypass graft (CABG).

### Claim at position 11

-43. (canceled)

### Claim 44

A pharmaceutical composition comprising a stable reduced form of a halogen compound, wherein said pharmaceutical composition is formulated for intravenous administration, administration by infusion, or oral administration.

### Claim at position 13

-172. (canceled)